Skip to main content
PMC home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Dec 19;36(1):31–38. [Article in Spanish] doi: 10.1157/13075929

Prevención primaria con estatinas, consensos y tablas de riesgo☆

F Miguel García a,1, A García Ortiz a,1, MJ Montero Alonso b
PMCID: PMC7676118  PMID: 15946613

The content is available as a PDF (154.9 KB).

Footnotes

☆

Miembros del Grupo de Información sobre Medicamentos de la Dirección General de Asistencia Sanitaria de Sacyl.

Bibliografía

  • 1.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. Informe completo disponible en: www.nhlbi.nih.gov/guidelines/cholesterol/ [DOI] [PubMed]
  • 2.Grupo de Trabajo de Prevención Cardiovascular del PAPPS Actividades preventivas cardiovasculares en atención primaria. Aten Primaria. 2003;32(Supl 2):15–29. [PubMed] [Google Scholar]
  • 3.Maiques Galán A., Villar Álvarez F. Tablas de riesgo cardiovascular y evidencias. En defense de la tabla de Framingham calibrada [respuesta de los autores] Aten Primaria. 2004;33:409–411. doi: 10.1016/S0212-6567(04)78898-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sever P., Dahlöf B., Poulter N., Wedel H., Beevers G., Caulfield M. Prevention of coronay and stroke events with atorvastatin in hypertensive patients who have average or Iower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158. doi: 10.1016/S0140-6736(03)12948-0. [DOI] [PubMed] [Google Scholar]
  • 5.Katerndahl D.A., Lawler W.R. Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease:a meta-meta-analysis. Am J Epidemiol. 1999;149:429–441. doi: 10.1093/oxfordjournals.aje.a009830. [DOI] [PubMed] [Google Scholar]
  • 6.Cholesterol and statins Bandolier [serie en Internet]. 2004 Abr, extra. Disponible en: www.ebandolier.com
  • 7.Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615–1622. doi: 10.1001/jama.279.20.1615. [DOI] [PubMed] [Google Scholar]
  • 8.Grupo de Trabajo de la Sociedad Española de Medicina Familiar y Comunitaria. Guía de prevención cardiovascular en atención primaria.Disponible en: http://www.papps.org/guiacardio/cardiovascular.pdf
  • 9.Wallsh J., Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291:2243–2252. doi: 10.1001/jama.291.18.2243. [DOI] [PubMed] [Google Scholar]
  • 10.Shepherd J., Baluw G., Murphy M.B., Bollen E., Buckley B.M., Cobbe S. Pravastatin in elderly individuals at risk of vascular disease. Lancet. 2002;360:623–629. doi: 10.1016/s0140-6736(02)11600-x. [DOI] [PubMed] [Google Scholar]
  • 11.Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., The West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1308. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  • 12.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998–3007. doi: 10.1001/jama.288.23.2998. [DOI] [PubMed] [Google Scholar]
  • 13.Pignone M., Phillips C., Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ. 2000;321:1–5. doi: 10.1136/bmj.321.7267.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Do statins have a role in primary prevention? Therapeutics Letter 2003, n.° 48. Disponible en: www.ti.ubc.ca
  • 15.Jackson P.R., Wallis E.J., Haq I.U., Ramsay E. Statins for primary prevention: at what coronary risk is safety assured? J Clin Pharmacol. 2001;52:439–446. doi: 10.1046/j.0306-5251.2001.01478.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Cucherat M., Lievre M., Gueyffier F. Clinical benefits of cholesterol lowering treatments. Meta-analysis of randomized therapeutic trials. Presse Med. 2000;29:965–976. [PubMed] [Google Scholar]
  • 17.Vrecer M., Turk S., Drinovec J., Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomiced trials. Int J Clin Pharmacol Ther. 2003;41:567–577. doi: 10.5414/cpp41567. [DOI] [PubMed] [Google Scholar]
  • 18.Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit. Impact of Statin Trials. Circulation. 1998;97:946–952. doi: 10.1161/01.cir.97.10.946. [DOI] [PubMed] [Google Scholar]
  • 19.Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arterioesclerosis Control de la colesterolemia en España, 2000 un instrumento para la prevención cardiovascular. Rev Esp Salud Pública. 2000;74:215–253. [PubMed] [Google Scholar]
  • 20.Ministerio de Sanidad y Consumo. Plan Integral de Cardiopatía isquémica 2004-2007. Madrid: Ministerio de Sanidad y Consumo; 2003.
  • 21.Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610. doi: 10.1016/s0195-668x(03)00347-6. [DOI] [PubMed] [Google Scholar]
  • 22.Ramos R., Solanas P., Cordón F., Rohlfs I., Elosua R., Sala J. Comparación de la function de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. Med Clin (Barc) 2003;121:521–526. doi: 10.1016/s0025-7753(03)74007-x. [DOI] [PubMed] [Google Scholar]
  • 23.Anderson K.M., Wilson P.W., Odel P.M., Kannel W.M. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–362. doi: 10.1161/01.cir.83.1.356. [DOI] [PubMed] [Google Scholar]
  • 24.Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., SCORE project group Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. doi: 10.1016/s0195-668x(03)00114-3. [DOI] [PubMed] [Google Scholar]
  • 25.Disponible en: www.fundacioninfosalud.org/cardio/cv_scalas.htm
  • 26.Maiques A. Valoración del riesgo cardiovascular.¿Qué tabla utilizar? Aten Primaria. 2003;32:586–589. doi: 10.1016/S0212-6567(03)79337-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Marrugat J., D’Agostino R., Sullivan L., Elosua R., Wilson P., Ordovás J. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Heath. 2003;57:634–638. doi: 10.1136/jech.57.8.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Marrugat J., Solanas P., D’Agostino R., Sullivan L., Ordovas J., Cordon F. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253–261. doi: 10.1016/s0300-8932(03)76861-4. [DOI] [PubMed] [Google Scholar]
  • 29.Aranceta J., Pérez C., Foz M., Mantilla T., Serra L., Moreno B., Grupo Colaborativo para el estudio Dorica fase II Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA. Med Clin (Barc) 2004;123:686–761. doi: 10.1016/s0025-7753(04)75331-2. [DOI] [PubMed] [Google Scholar]
  • 30.Marrugat J. Acerca de la participación en los estudios epidemiológicos. Med Clin (Barc) 2000;114:115. doi: 10.1016/s0025-7753(00)71208-5. [DOI] [PubMed] [Google Scholar]
  • 31.The Second Joint Task Force of European and other Societies on Coronary Prevention Prevention of coronary heart disease in clinical practice. European Heart Journal. 1998;19:1434–1503. doi: 10.1053/euhj.1998.1243. [DOI] [PubMed] [Google Scholar]
  • 32.Maiques A., Antón F., Franch M., Albert X., Aleixandre E., Collado Á. Riesgo cardiovascular del SCORE comparado con el de Framingham. Consecuencias del cambio propuesto por las sociedades europeas. Med Clin (Barc) 2004;123:681–685. doi: 10.1016/s0025-7753(04)75330-0. [DOI] [PubMed] [Google Scholar]
  • 33.Gómez MA, García L, Sánchez A, González LJ, Santos I, Ramos E, et al. Changes in use of antihipertensive medication in spanish primare care during last five years. Comunicación presentada al Congreso Europeo de Hipertensión. París, 2004. Disponible en http://www.laalamedilla.org/Investigacion/comunicaciones2004.htm
  • 34.Ramos R., Marrugat J. Valoración del riesgo cardiovascular en la población. In: Del Río Ligori A., editor. Mannual de cardiología preventive. SMC; Madrid: 2005. [Google Scholar]
  • 35.Evans J.M., Wang J., Morris A.D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who have a myocardial infarction: cross sectional and cohor studies. BMJ. 2003;324:939–1013. doi: 10.1136/bmj.324.7343.939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lotufo P.A., Gaziano M., Chae C.U., Ajani U.A., Moreno-John G., Buring J.E. Diabetes and all cause and coronary heart disease mortality among US male phisicians. Arch Intern Med. 2001;161:242–247. doi: 10.1001/archinte.161.2.242. [DOI] [PubMed] [Google Scholar]
  • 37.Lee Ch.D., Folsom A.R., Pankow J.S., Brancati F.L. Cardiovascular events in diabetic and no diabetic aduts with or without history of myocardial infarction. Circulation. 2004;109:855–860. doi: 10.1161/01.CIR.0000116389.61864.DE. [DOI] [PubMed] [Google Scholar]
  • 38.Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC) Adaptación española de la Guía Europea de Prevención Cardiovascular. Aten Primaria. 2004;34:427–432. doi: 10.1016/S0212-6567(04)78927-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES